CAP Antibiotics May Not Benefit Nonsevere COVID-19 Infections - Summary - MDSpire
From the Journals

CAP Antibiotics May Not Benefit Nonsevere COVID-19 Infections

A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.

  • By

  • Andrea Surnit

  • May 13, 2026

  • 4 min

Share

A large retrospective cohort study analyzed the effects of empiric antibiotic treatment on patients hospitalized with nonsevere COVID-19 infections. It enrolled over 520,000 immunocompetent adults across 1,053 hospitals, revealing that antibiotic use did not significantly improve clinical outcomes and was linked to slightly increased risks of deterioration and in-hospital mortality. The study highlights the low rates of confirmed bacterial coinfections, emphasizing the need for better antibiotic stewardship in this patient group, as discussed by lead author Dr. Michael S. Pulia of the University of Wisconsin-Madison.

Original Source(s)

CAP Antibiotics May Not Benefit Nonsevere COVID-19 Infections

  • by Andrea Surnit

  • May 13, 2026

Related Content

7 Days Noninferior in Bacteremia

BALANCE compared 7 vs 14 days of treatment among hospitalized patients with bloodstream infections.

FDA Clears AI Sepsis Warning System

An FDA-cleared AI tool developed at Johns Hopkins detects sepsis up to 48 hours earlier than clinicians — and has cut related deaths by 18%.

How Social Contact Shapes Gut Microbes

Cooperative behavior linked to shared anaerobic gut bacteria

  • May 11, 2026

  • 2 min